AI-driven drug discovery services
See open opportunities
Isomorphic Labs' mission is to use AI and machine learning methods to accelerate and improve the drug discovery process.
Some candidates hear
back within 2 weeks
CEO of Otta
The discovery of new drugs is essential for medical innovations, but the process is lengthy, high-risk, and expensive. This is due to manual research and analysis processes that are prone to human error and time-consuming workflows, raising the question as to whether AI could reduce these pitfalls.
Rather than bolting ML onto the existing drug discovery process, Isomorphic Labs is reimagining everything from first principles with an AI-first approach, leveraging machine learning to build predictive and generative models of biological phenomena to understand how novel drugs could perform. The company differentiates itself from other AI-driven drug discovery startups by being a direct subsidiary of Alphabet, with access to resources, computing power, and partnerships with teams within DeepMind.
AI-driven drug discovery itself may not be novel, but the approach the company is taking, as well as its direct links with Alphabet, Google, and DeepMind present great potential for the company to disrupt the market with the best talent and technology.
Experience as Founder & CEO of Elixir Studios. Founder and CEO of DeepMind since 2010.
Diversity & Inclusion at Isomorphic Labs
Isomorphic Labs is hiring for 5 jobs on Otta!